Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Rhythm Pharmaceuticals, Inc. (RYTM)

29.08   -1.39 (-4.56%) 01-27 16:00
Open: 30.43 Pre. Close: 30.47
High: 30.54 Low: 28.75
Volume: 483,720 Market Cap: 1,639(M)

Technical analysis

as of: 2023-01-27 4:47:42 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 37.61     One year: 40.86
Support: Support1: 27.7    Support2: 23.04
Resistance: Resistance1: 32.2    Resistance2: 34.99
Pivot: 30.83
Moving Average: MA(5): 30.26     MA(20): 30.44
MA(100): 26.21     MA(250): 16.28
MACD: MACD(12,26): 0.4     Signal(9): 0.6
Stochastic oscillator: %K(14,3): 32.5     %D(3): 38.5
RSI: RSI(14): 47.1
52-week: High: 34.99  Low: 3.03
Average Vol(K): 3-Month: 622 (K)  10-Days: 559 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ RYTM ] has closed above bottom band by 16.0%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 30.61 - 30.79 30.79 - 30.93
Low: 28.33 - 28.56 28.56 - 28.74
Close: 28.77 - 29.12 29.12 - 29.38

Company Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Headline News

Sat, 28 Jan 2023
DekaBank Deutsche Girozentrale acquires 30,000 shares of Rhythm ... - Best Stocks

Sat, 28 Jan 2023
Rhythm Pharmaceuticals Inc.'s (NASDAQ:RYTM) Forecasted Growth ... - Marketing Sentinel

Fri, 27 Jan 2023
30000 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ... - MarketBeat

Mon, 23 Jan 2023
Rhythm Pharmaceuticals (RYTM) Announces Publication of ... - StreetInsider.com

Thu, 19 Jan 2023
Know Who to Follow! Here are the Top 10 U.S. Analysts of 2022 ... - TipRanks

Mon, 09 Jan 2023
3 Breakout Growth Stocks to Buy for the Long Haul - The Motley Fool

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 56 (M)
% Held by Insiders 3.914e+007 (%)
% Held by Institutions 0.3 (%)
Shares Short 8,440 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.8649e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 128.3
Return on Equity (ttm) -31.6
Qtrly Rev. Growth 1.666e+007
Gross Profit (p.s.) 166.68
Sales Per Share -31.66
EBITDA (p.s.) 1.34737e+006
Qtrly Earnings Growth -3.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -180 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0.9
Price to Book value 0
Price to Sales -0.92
Price to Cash Flow 10.96

Stock Dividends

Dividend 0
Forward Dividend 8.09e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.